Volume | 2,161,007 |
|
|||||
News | - | ||||||
Day High | 2.46 | Low High |
|||||
Day Low | 2.01 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Emergent Biosolutions Inc | EBS | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
2.15 | 2.01 | 2.46 | 2.39 | 2.14 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
10,449 | 2,161,007 | US$ 2.27 | US$ 4,913,631 | - | 1.81 - 16.6643 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:59:55 | 3 | US$ 2.36 | USD |
Emergent Biosolutions Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.67B | 51.81M | - | 1.12B | -223.8M | -4.32 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Emergent Biosolutions News
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EBS Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.00 | 2.46 | 1.96 | 2.10 | 1,439,452 | 0.35 | 17.5% |
1 Month | 2.15 | 2.46 | 1.81 | 2.14 | 1,450,273 | 0.20 | 9.3% |
3 Months | 4.39 | 4.68 | 1.81 | 2.94 | 1,739,154 | -2.04 | -46.47% |
6 Months | 8.57 | 9.96 | 1.81 | 4.89 | 1,915,775 | -6.22 | -72.58% |
1 Year | 12.40 | 16.6643 | 1.81 | 7.48 | 1,677,872 | -10.05 | -81.05% |
3 Years | 82.74 | 127.20 | 1.81 | 26.85 | 1,029,154 | -80.39 | -97.16% |
5 Years | 73.75 | 137.61 | 1.81 | 38.23 | 826,197 | -71.40 | -96.81% |
Emergent Biosolutions Description
Emergent BioSolutions offers public health products to government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccine, device, and therapeutic products. |